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INTRODUCTION
Anticoagulant drugs are used to prevent the occur-
rence of complications of certain conditions (prophy-
lactic use), whereas in some states it is administered 
as a medication (therapeutic use). Atrial fi brillation 
(AF), deep vein thrombosis, pulmonary embolism, 
and other hypercoagulable conditions are the most 
common causes for the introduction of anticoagulant 
therapy (1). Mostly, anticoagulants are divided into two 
groups: vitamin K antagonists (VKA) such as warfarin, 
and nonVKA or direct oral anticoagulants (DOACs) 
such as dabigatran, rivaroxaban, apixaban and edox-
aban. Warfarin has been the major anticoagulant drug 
for many years, aff ecting its wide application and low 
cost (1). It blocks the enzyme vitamin K epoxide reduc-
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tase, which turns vitamin K into its active form. With-
out suffi  cient amount of active vitamin K formulation, 
there will be no adequate formation of factors II, VII, 
IX and X that reduce blood coagulability. Warfarin is 
administered per os once daily, provided that the dose 
is titrated to the values of the International Normalized 
Ratio (INR, blood coagulation parameter). When war-
farin is introduced, heparin therapy is required until 
the target INR is reached. Th e INR is generally main-
tained in the range of 2-4. Warfarin is removed from 
the body via liver enzymes (1). Th e fact that optimal 
doses of INR are diffi  cult to achieve and that the ther-
apeutic width of the drug itself is very narrow has led 
to the need for new medicines. DOACs have appeared 
on the market in the last 10 years. Dabigatran is a fac-
tor IIa inhibitor, whereas rivaroxaban, edoxaban and 
apixaban are factor Xa inhibitors (2). Th e advantage 
over warfarin is that they are applied at fi xed doses and 
their application does not require INR control to eval-
uate effi  cacy. Caution is advised when dosing DOAC 
in patients with impaired renal function and with drug 
interactions (3,4). Renal function is estimated by glo-
merular fi ltration rate (eGFR). In case of eGFR less 
than 50 mlmin-11.73m2, it is necessary to adjust the 
dose of dabigatran and rivaroxaban (4). Bleeding (gas-
trointestinal and genitourinary) is the most common 
complication of taking anticoagulant therapy (5). Th e 
CHADS-VASc score is used to assess the risk in pa-
tients with AF and includes the following: congestive 
heart failure (or systolic left  ventricular dysfunction), 
hypertension, age >65 years, diabetes mellitus, previ-
ous stroke or transient ischemic attack or thromboem-
bolism, vascular disease and female sex, with a number 
of points the sum of which (0-9) ultimately show the 
degree of the risk of stroke in these patients (6). Th e 
HAS-BLED score (includes hypertension data, abnor-
mal renal and liver function, stroke in history, previous 
bleeding, INR that is diffi  cult to maintain in the set val-
ues, age and drug or alcohol consumption) shows the 
risk of major bleeding with points on this scale (0-9) 
(7). 
Th e likelihood of bleeding increases with age due to the 
older population having many associated diseases and 
taking more therapy medications. Drugs that aff ect the 
permeability of glycoprotein reagents (P-gp) and par-
ticular CYP enzymes in the liver can signifi cantly aff ect 
the concentration of dabigatran; statins can increase 
dabigatran concentration in the blood by 200% and re-
sult in increased effi  cacy of dabigatran (8). 
Th e aim of this study was to determine the prevalence 
and type of bleeding between warfarin and DOACs in 
emergency patients taking these agents for the previ-
ously known indications adjusted to the degree of kid-
ney disease. 
PATIENTS AND METHODS
Th e study included 83 patients (out of 3488 patients 
examined within 7 months) from Emergency Unit, 
Department of Internal Medicine, Merkur University 
Hospital during the period from December 1, 2018 un-
til June 1, 2019. All patients involved in the study were 
taking anticoagulant therapy and had AF. 
Patients were divided into two groups, as follows: 
group A (22 patients, 8 male) were receiving warfarin 
and group B patients (61 patients, 19 male) were tak-
ing DOACs (dabigatran 29, rivaroxaban 20 and apix-
aban 12 patients). Rivaroxaban was started at a dose of 
20 mg once daily and dabigatran at a dose of 150 mg 
twice daily in patients with eGFR ≥50 mlmin-11.73m2. 
In patients with eGFR >30 and <50 mlmin-11.73m2, ri-
varoxaban was started at a dose of 15 mg once daily 
and dabigatran at a dose of 110 mg twice daily. Apix-
aban was started at 5 mg twice daily. Th e mean age was 
80.72±7.89 years in group A and 80.95±6.78 years in 
group B. All patients were under appropriate thera-
py for other comorbidities (duration of hypertension 
12±5 years, duration of AF 6±3 years, body mass index 
(BMI) 34.6±4.1 kg/m2).
Patients were compared and stratifi ed according to the 
CHADS-VASc score (3.65 and 3.74 in group A and 
B, respectively) and HAS-BLED score (5.35 and 4.7 
in group A and B, respectively), as well as according 
to eGFR calculated using the Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD-EPI) formula 
(42.71±15.02 and 47.42±16.19 mlmin-11.73m2 in group 
A and B, respectively). A HAS-BLED score ≥3 suggests 
an increased risk of experiencing bleeding complica-
tions (7). Th is study was approved by the local Ethics 
Committee and a written informed consent to partici-
pate was provided by study patients.
Th e STATISTICA 13.1 soft ware was used to compare 
total bleeding between the groups and χ2-test to test 
diff erences between the groups.
RESULTS
Th e main cause of emergency attendance was visible 
bleeding in 43 (51.81%) patients. Total number of 
patients divided according to localization of verifi ed 
bleeding depending on the drug used is shown in Table 
1. Th ere were no statistically signifi cant between-group 
diff erences in renal function, age, duration of hyper-
tension, AF and CHADS-VASc score (Table 1). 
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Table 1. Percentage of bleeding according to localization and 
drug used
Verifi ed bleeding Warfarin, % (n) DOACs, % (n)
Bleeding from lower gastrointestinal tract 46.67% (7/15) 42.86% (9/21)
Bleeding from upper gastrointestinal tract 33.33% (5/15) 28.57% (6/21)
Hematuria 13.33% (2/15) 23.81% (5/21)
Skin hematoma 6.67% (1/15) 4.76% (1/21)
Total (all patients taking certain drug) 68.18% (15/22) 34.42% (21/61)
DOACs = direct oral anticoagulants
Patients on DOAC on more than 3 diff erent drugs such 
as atorvastatin or pantoprazole or amiodarone were 
more prone to bleeding. Th e number of active bleeding 
according to the chronic kidney disease (CKD) stage 
is shown in Table 2. Th e χ2-test was used to compare 
total bleeding between the groups (χ2=7.51; p=0.006). 
Bleeding was statistically signifi cantly lower in group B 
(DOAC) than in group A (warfarin). 
Diff erence in gastrointestinal bleeding was compared 
between the groups by use of χ2-test (χ2=7.78; p=0.005). 
Gastrointestinal bleeding was statistically signifi cantly 
more frequent in group A as compared with group B 
(Table 2). 
Table 2. Number of bleeding patients according to kidney 
function and type of drug
eGFR CKD EPI stage (mlmin-11.73m2 ) Warfarin, n (%) DOACs, n (%)
G2 (60-89) 5/6 (83.33%) 5/14 (35.71%)
G3 (30-59) 6/10 (60.00%) 12/36 (33.33%)
G4 (15-29) 4/6 (66.66%) 4/11 (36.36%)
Total (all patients taking certain drug) 15/22 (68.18%) 21/61 (34.42%)
eGFR = estimated glomerular fi ltration rate (CKD-EPI formula, mL/
min/1.73m2); DOACs = direct oral anticoagulants
DISCUSSION
Patients with AF oft en present to emergency depart-
ment because of symptoms such as shortness of breath, 
chest pain and palpitations, as well as bleeding (9). Pre-
scribing of DOACs is increasing in every day medicine 
and ever more AF patients take these drugs (2,3), as 
also demonstrated in the present study. DOACs do not 
require bridging or INR monitoring, which is an im-
portant advantage of DOACs. Th ey may improve pa-
tient adherence, but long-term medication may cause 
bleeding, as shown in this study. With initiation of a 
new long-term medication, it is recommended that 
these patients be followed over time to ensure the dos-
age is correct and adverse eff ects are managed (9). 
Th is study confi rmed that bleeding was the most com-
mon side eff ect of taking anticoagulant therapy. It occurs 
more frequently in elderly population and in the popula-
tion using multiple drugs in their chronic therapy. Drugs 
that have eff ects on anticoagulant medication, especial-
ly on warfarin and dabigatran, include various agents; 
they act as the permeability glycoprotein (P-gp) inducers 
(rifampin and St. John’s wort), or as inhibitors (statins, 
antiarrhythmics, antifungals, antiviral drugs, and many 
others) (9). Caution should be exercised by the family 
medicine physician when ordering additional medica-
tion in these patient groups. Th is primarily refers to pre-
scribing particular antibiotics and education of patients 
taking nonsteroidal anti-infl ammatory drugs (10). 
Dosage of certain drugs depends on eGFR, which makes 
it a very important factor in this group of patients. In 
case of decreased eGFR, it is necessary to adjust dos-
es of dabigatran and rivaroxaban. In the literature, im-
proper dosing of these drugs or unrecognized kidney 
disease may increase their toxicity and consequently 
the frequency of side eff ects of this treatment, as shown 
in our previous articles (9,11). Patient education is also 
of utmost importance in order to reduce excessive an-
algesic consumption or other factors that may have an 
eff ect on this drug group (12). Th e eff ects of DOACs 
may be prolonged in patients with underlying undiag-
nosed CKD. Th erefore, important questions to ask a 
patient having some bleeding while on DOACs include 
the timing of their last DOAC ingestion and whether 
they have any underlying renal disorders. Th e decision 
to use a reversal agent in patients having bleeding while 
taking DOACs must be made on a case-by-case basis 
with the help of a multi-disciplinary treatment team 
(13-15). Given our results with much more patients on 
DOACs than VKA (warfarin), we believe that both phy-
sicians and patients are becoming more accustomed to 
the use of DOACs in clinical practice. Many questions 
on how to optimally use these agents in specifi c clin-
ical situations remain unresolved (14). Th e European 
Heart Rhythm Association coordinates a unifi ed way 
of informing physicians on the use of diff erent DOACs 
(14). Th e real world population is sicker and more frag-
ile than patients in randomized controlled trials. Th ese 
sicker, more fragile group of patients are at a higher risk 
of bleeding. Future work is needed to establish reliable 
follow-up of these patients in healthcare system.
CONCLUSIONS
Th e results of this study confi rmed the safety of DO-
ACs in elderly population (>80 years) with 3 and more 
comorbidities. Bleeding as a cause of emergency re-
sponse was signifi cantly more frequent in patients on 
warfarin compared to patients taking DOACs. Addi-
tional studies are needed to check the diff erence be-
tween individual DOACs and to determine diff erence 
between warfarin and DOACs in patients with severely 
impaired renal function.
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SAŽETAK
KRVARENJE KAO GLAVNI UZROK HITNOSTI U BOLESNIKA NA ANTIKOAGULANTNOJ TERAPIJI
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3Klinička bolnica Dubrava, Klinika za unutarnje bolesti; Zagreb, 4Klinička bolnica Sveti Duh, Objedinjeni hitni bolnički prijam, 
Zagreb i Medicinski fakultet Osijek, Klinika za anesteziju, reanimatologiju i intenzivno liječenje, Osijek, Hrvatska
Starenjem populacije stanja koja zahtijevaju antikoagulantnu terapiju ima sve više, čime uporaba antikoagulantne terapije 
u svijetu raste. Budući da krvarenje nastaje kod uporabe varfarina kao i direktnih antikoagulansa, cilj ovoga istraživanja bio 
je pokazati postoji li razlika u učestalosti krvarenja kao glavnog uzroka hitnosti u ovih bolesnika ovisno o primijenjenom 
antikoagulansu. Metode: U istraživanje su bila uključena 83 bolesnika na antikoagulantnoj terapiji s kroničnom bubrežnom 
bolešću stadija 2-4, pregledana u Hitnom prijmu Kliničke bolnice Merkur u razdoblju od sedam mjeseci. Skupina A obuhva-
ćala je 22 bolesnika (8 muškaraca) na varfarinskoj terapiji, a skupina B 61 bolesnika (19 muškaraca) na direktnoj oralnoj 
antikoagulantnoj terapiji. Srednja dob u skupini A bila je 80,77 godina, a u skupini B 80,95 godina. Nisu nađene razlike u 
komorbiditetima među skupinama. Doze antikoagulantnih lijekova bile su prilagođene bubrežnoj funkciji. Rezultati: U skupini 
A je glavni uzrok hitnosti bilo krvarenje u 15/22 (68,18%) bolesnika (većinom gastrointestinalnog podrijetla), dok je u skupini 
B krvarenje pronađeno u 21/61 (34,42%) bolesnika. Za provjeru statističke značajnosti razlike krvarenja kao glavne hitnosti 
među dvjema skupinama bolesnika primijenjen je χ2-test (χ2=7,501; p<0,01). Zaključak: Primjenom direktnih oralnih 
antikoagulantnih lijekova u dozi prilagođenoj bubrežnoj funkciji bilježi se statistički značajno manje krvarenja kao glavnog 
uzroka hitnosti u usporedbi s varfarinom.
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